Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
The launch event brought together policymakers, healthcare leaders, surgeons, and members of the medical fraternity to discuss the transformative role of robotic-assisted surgery
Founded by serial entrepreneur Dinakara Nagalla, the platform enters the Indian market with 30,000 users, and 500 wellbeing professionals
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
Subscribe To Our Newsletter & Stay Updated
